Clinical bottom line
Novel mRNA therapeutic agents beyond vaccines represent an emerging class of treatments with potential for allergic and allergic-like reactions, though current clinical experience remains limited. Early evidence suggests that such reactions may resemble those observed with mRNA vaccines, including immediate hypersensitivity and anaphylaxis, but the incidence, mechanisms, and risk factors are not yet well characterized. Clinicians should maintain vigilance for allergic reactions when administering these agents, apply established protocols for diagnosis and management adapted from vaccine experience, and report adverse events to improve understanding. Further research is needed to define optimal screening, prevention, and treatment strategies tailored to this novel therapeutic modality.
What the evidence shows
Messenger RNA (mRNA) technology, initially developed for vaccines, is rapidly expanding into therapeutic agents for diverse diseases (Kallen et al., 2013). The success of COVID-19 mRNA vaccines has accelerated interest in mRNA-based drugs beyond infectious disease prevention. However, allergic reactions to mRNA vaccines, including anaphylaxis, have been documented and studied extensively, providing a foundational framework for anticipating similar issues with novel mRNA therapeutics (Rubin et al., 2021; Bekis Bozkurt et al., 2024).
Allergic and allergic-like reactions to mRNA vaccines typically occur within minutes to hours post-administration and may involve IgE-mediated mechanisms or non-IgE pathways such as complement activation-related pseudoallergy (CARPA) (Anderson et al., 2000; Anderson et al., 2007). The lipid nanoparticle (LNP) delivery system, which encapsulates the mRNA, is a suspected trigger, with polyethylene glycol (PEG) components implicated in hypersensitivity (Rubin et al., 2021). These insights are relevant to novel mRNA therapeutics, which often employ similar LNP platforms.
Clinical reports and pharmacovigilance data indicate that allergic reactions to mRNA vaccines are rare but can be severe, necessitating immediate recognition and treatment with epinephrine and supportive care (Bekis Bozkurt et al., 2024). Diagnostic approaches include detailed clinical history, skin testing for PEG and other excipients, and graded challenge protocols when indicated (Anderson et al., 2007). These strategies are currently extrapolated to novel mRNA therapeutics due to limited direct evidence.
The broader category of allergic reactions to drugs and therapeutic agents encompasses diverse mechanisms and presentations, underscoring the complexity of diagnosis and management (Anderson et al., 2007). The novelty of mRNA therapeutics adds uncertainty regarding immunogenicity and potential for sensitization, especially as these agents target different tissues and disease pathways compared to vaccines.
Caveats and uncertainty
The evidence base for allergic reactions to mRNA therapeutics beyond vaccines is sparse and largely inferential. Most data derive from vaccine experience, which may not fully predict reactions to therapeutics with different dosing regimens, target populations, or molecular constructs (Bekis Bozkurt et al., 2024). The immunologic mechanisms underlying hypersensitivity to mRNA drugs remain incompletely understood, with ongoing debate about the relative roles of IgE, complement activation, and other pathways (Anderson et al., 2000).
Diagnostic testing for PEG and LNP components lacks standardization and validation in this context, limiting sensitivity and specificity (Rubin et al., 2021). Furthermore, the rarity of severe reactions challenges the development of robust predictive models. There is also uncertainty about cross-reactivity between different mRNA formulations and whether prior tolerance to one mRNA vaccine predicts safety with a novel mRNA therapeutic.
Clinical management guidelines specific to mRNA therapeutics are not yet established, and current recommendations rely on adaptation from vaccine protocols and general drug allergy principles (Bekis Bozkurt et al., 2024). Long-term safety data are lacking, and the potential for delayed or chronic hypersensitivity reactions remains unexplored.
How this may change practice
As mRNA therapeutics enter clinical practice, allergists and other clinicians should anticipate allergic reactions as a potential adverse event and incorporate vigilance into monitoring protocols. Pre-treatment risk assessment may include detailed allergy histories focusing on prior reactions to mRNA vaccines, PEG-containing products, or other excipients.
Clinicians should apply established diagnostic approaches from vaccine allergy management, including skin testing and graded challenges, while recognizing their limitations and the need for individualized assessment. Immediate availability of emergency treatment for anaphylaxis is essential when administering these agents.
Reporting suspected allergic reactions to pharmacovigilance systems will be critical to accumulate safety data and refine management strategies. Multidisciplinary collaboration between allergists, immunologists, and treating specialists will facilitate optimal care.
In the longer term, development of standardized diagnostic assays, identification of biomarkers predictive of hypersensitivity, and clinical trials assessing desensitization protocols may improve safety and accessibility of mRNA therapeutics for allergic patients.